---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000236"
form_type: "8-K"
ticker: null
cik: "0001602078"
company_name: "Nemaura Medical Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:57:38.346973+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nemaura Medical restates Q1 and Q2 FY2022 financials; identifies material weakness in internal controls

## Summary
- Net loss for Q1 (June 30, 2022) decreased ~$90K to ~$3.889M; Q2 (Sept 30, 2022) decreased ~$223K to ~$3.856M.
- Errors: incorrect foreign currency translation on mark-to-market contract and omitted debt issuance costs in loan interest computation.
- Material weakness in internal control over financial reporting identified; disclosure controls ineffective as of June 30 and Sept 30, 2022.
- Q3 10-Q for period ended Dec 31, 2022 expected to be delayed beyond Feb 21, 2023 extended deadline; no impact on sales, gross profit, or cash.

## SEC filing metadata
- accession: 0001079973-23-000236
- form_type: 8-K
- cik: 0001602078
- company_name: Nemaura Medical Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000236/0001079973-23-000236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000236/nmra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000236
- JSON: https://secwatch.observer/filing/0001079973-23-000236.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000236.txt

## Key facts
- Auditor Changes
  Nemaura Medical Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: On February 17, 2023, the management and the Audit Committee of the Board of Directors of Nemaura Medical, Inc. (the "Company") concluded that the following financial statements should be restated and should no longer be relied upon
  evidence_url: https://www.sec.gov/Archives/edgar/data/1602078/000107997323000236/0001079973-23-000236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.